rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Robin Shane Readnour

Director

Company insider

Files Form 4 as: Director, AN2 Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
59
Buys
8
Sells
6
Bought
$2.7M
Sold
$745K
Companies
1
Companies where not an officer
1
First trade
29 Mar 2022
Last trade
9 Sep 2026
Last filed
11 Sep 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
ANTX AN2 TherapeuticsDirector · Biotechnology · last 9 Sep 20268 buys · 6 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
204Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
9 Sep 2026filed 11 Sep 2026ANTX AN2 TherapeuticsBiotechnologySEC FORM 4 Sold$3,151523 at $6.02filing
9 Sep 2026filed 11 Sep 2026ANTX AN2 TherapeuticsBiotechnologySEC FORM 4 Sold$3,524585 at $6.02filing
9 Sep 2026filed 11 Sep 2026ANTX AN2 TherapeuticsBiotechnologySEC FORM 4 Sold$3,148523 at $6.02filing
9 Sep 2026filed 11 Sep 2026ANTX AN2 TherapeuticsBiotechnologySEC FORM 4 Sold$3,522585 at $6.02filing
8 Sep 2026filed 8 Sep 2026ANTX AN2 TherapeuticsBiotechnologySEC FORM 4 Sold$28K4,725 at $6.02filing
8 Sep 2026filed 8 Sep 2026ANTX AN2 TherapeuticsBiotechnologySEC FORM 4 Sold$32K5,294 at $6.02filing
8 Sep 2026filed 8 Sep 2026ANTX AN2 TherapeuticsBiotechnologySEC FORM 4 Sold$28K4,725 at $6.02filing
8 Sep 2026filed 8 Sep 2026ANTX AN2 TherapeuticsBiotechnologySEC FORM 4 Sold$32K5,294 at $6.02filing
3 Sep 2026filed 8 Sep 2026ANTX AN2 TherapeuticsBiotechnologySEC FORM 4 Sold$17K2,877 at $6.07filing
3 Sep 2026filed 8 Sep 2026ANTX AN2 TherapeuticsBiotechnologySEC FORM 4 Sold$20K3,223 at $6.07filing
3 Sep 2026filed 8 Sep 2026ANTX AN2 TherapeuticsBiotechnologySEC FORM 4 Sold$17K2,877 at $6.07filing
3 Sep 2026filed 8 Sep 2026ANTX AN2 TherapeuticsBiotechnologySEC FORM 4 Sold$20K3,223 at $6.07filing
17 Aug 2026filed 19 Aug 2026ANTX AN2 TherapeuticsBiotechnologySEC FORM 4 Sold$100K16,696 at $6.01filing
17 Aug 2026filed 19 Aug 2026ANTX AN2 TherapeuticsBiotechnologySEC FORM 4 Sold$112K18,706 at $6.01filing
17 Aug 2026filed 19 Aug 2026ANTX AN2 TherapeuticsBiotechnologySEC FORM 4 Sold$100K16,696 at $6.01filing
17 Aug 2026filed 19 Aug 2026ANTX AN2 TherapeuticsBiotechnologySEC FORM 4 Sold$112K18,706 at $6.01filing
19 Mar 2026filed 23 Mar 2026ANTX AN2 Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,724filing
19 Mar 2026filed 23 Mar 2026ANTX AN2 Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—20,724filing
19 Mar 2026filed 23 Mar 2026ANTX AN2 Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—23,742filing
19 Mar 2026filed 23 Mar 2026ANTX AN2 Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,724filing

News

Anthem (NASDAQ:ANTX) Director Robin Shane Readnour Sells 10,019 Sharesdailypolitical.com · 9 Sep 2026

1 headline in the last 90 days name Robin Shane Readnour; 0 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care14

Buys in green, sells in red, by the company’s sector.

Related people

Kabeer AzizDirector · Director at AN2 Therapeutics, filing Form 4 there in the last year
Gilbert Lynn MarksDirector · Director at AN2 Therapeutics, filing Form 4 there in the last year
Patricia A. MartinDirector · Director at AN2 Therapeutics, filing Form 4 there in the last year
Cameron C. Trenor IIIChief Medical Officer · Chief Medical Officer at AN2 Therapeutics, filing Form 4 there in the last year
Sarah Joanne WilliamsPrincipal Accounting Officer · Principal Accounting Officer at AN2 Therapeutics, filing Form 4 there in the last year
Margaret M. FitzPatrickDirector · Also traded ANTX in the last 90 days